Reacción a "Reaction to data shared by Moderna on its bivalent Omicron vaccine"

These are encouraging data, although we need more details than those presented in the company's press release. It is good news that the company announces that the trial objectives have been met in terms of immunogenicity and that the criteria for non-inferiority to the original vaccine have been met. A vaccine that shows effectiveness at the level of neutralising antibodies to omicron is needed as soon as possible for the next waves to protect vulnerable populations.

It is now up to the regulatory agencies to evaluate all the data from the study and issue their assessment.